RUVBL1 and non-small cell lung carcinoma: Yenerall et al. [37] discovered a structurally similar molecule for RUVBL1/2 inhibition (known as compound B) and assessed its transcriptomic effects in two non-small cell lung cancer cells (NSCLCs).